DUNP-19

N/A

Report date: 2025/11/21 17:15:31

Base Information

Drug NameDUNP-19
Drug Alias NameLutetium-177 labeled humanized monoclonal antibody targeting leucine rich repeat containing 15 (LRRC15) (Radiopharm Theranostics)DUNP-19DUNP19
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Nuclides > Lutetium > 177Lu +[5] 
Mechanisms of ActionAnti-LRRC15
TargetsLeucine-rich repeat-containing protein 15
Therapy Area/IndicationsOsteosarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRadiopharm Theranostics LtdUniversity Of California
China Registration ClassN/A

Develop Information

Active CompaniesRadiopharm Theranostics Ltd
Inactive CompaniesN/A
Active IndicationsOsteosarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A